US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Tower Ltd (TWR) 銘柄情報

Tower Ltd (TWR)

1.545

0.035

(2.32%)

終了 6月12日 3:00PM

Tower Ltd (TWR) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.545

( 2.32% )

買値

1.51

売値

1.69

出来高

194,192

1.52 日の範囲 1.57

1.345 52 週間の範囲 1.855

時価総額

前日終値

1.51

始値

1.55

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 390,137

発行済株式数

343,411,351

配当利回り

0.22 (12.83%)

PER

11.8

1 株当たり利益 (EPS)

0.16

歳入

606.02M

純利益

56.79M

Tower Limited provides general insurance products in New Zealand and the Pacific Islands. Its insurance products include car, house, contents, contract works and renovation cover, landlord, boat, business, travel, pet, renters, house and contents bundle, electric vehicle, motorbike and motorcycle, l... Tower Limited provides general insurance products in New Zealand and the Pacific Islands. Its insurance products include car, house, contents, contract works and renovation cover, landlord, boat, business, travel, pet, renters, house and contents bundle, electric vehicle, motorbike and motorcycle, lifestyle block, caravan or trailer, as well as motorhome, campervan and RV insurance. It also offers multi-policy discount insurance. Tower Limited was founded in 1869 and is headquartered in Auckland, New Zealand. 詳細を表示

セクター

Finance

業界

Insurance

ウェブサイト

www.tower.co.nz

本社

Auckland, New Zealand

設立

1869

Tower Ltd is listed in the Finance sector of the オーストラリア証券取引所 with ticker TWR. The last closing price for Tower was AUD1.51. Over the last year, Tower shares have traded in a share price range of AUD 1.345 to AUD 1.855.

Tower currently has 343,411,351 shares in issue. The market capitalisation of Tower is AUD530.57 million. Tower has a price to earnings ratio (PE ratio) of 11.80.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.095	-5.79268292683	1.64	1.64	1.52	73168	1.58382439	DE
4	-0.185	-10.6936416185	1.73	1.8	1.51	76872	1.61581026	DE
12	0.005	0.324675324675	1.54	1.8	1.51	61005	1.62455298	DE
26	-0.16	-9.38416422287	1.705	1.855	1.49	85642	1.66618373	DE
52	0.135	9.57446808511	1.41	1.855	1.345	64201	1.62588842	DE
156	0.995	180.909090909	0.55	1.855	0.51	66931	1.07676582	DE
260	0.86	125.547445255	0.685	1.855	0.505	58775	0.94360682	DE

TWR - Frequently Asked Questions (FAQ)

What is the current Tower Ltd share price?

The current share price of Tower Ltd is AUD 1.545

How many Tower Ltd shares are in issue?

Tower Ltd has 343,411,351 shares in issue

What is the market cap of Tower Ltd?

The market capitalisation of Tower Ltd is AUD 530.57M

What is the 1 year trading range for Tower Ltd share price?

Tower Ltd has traded in the range of AUD 1.345 to AUD 1.855 during the past year

What is the PE ratio of Tower Ltd?

The price to earnings ratio of Tower Ltd is 11.8

What is the cash to sales ratio of Tower Ltd?

The cash to sales ratio of Tower Ltd is 1.1

What is the registered address of Tower Ltd?

The registered address for Tower Ltd is 136 Fanshawe Street, Auckland, 1142

What is the Tower Ltd website address?

The website address for Tower Ltd is www.tower.co.nz

Which industry sector does Tower Ltd operate in?

Tower Ltd operates in the Insurance sector

Nelson2

Nelson2 6分前

A R/S is coming. And yes there is always a unicorn but vast majority are negative to shareholders I’m out, but good luck to you

WHITTENHALLJR

WHITTENHALLJR 6分前

Hopefully not here lol

Homebrew

Homebrew 6分前

😆 🤣 😂. That video is pathetically cringe.

Lime Time

Lime Time 7分前

No one to contest and zero debt. Should get scooped up rather quickly at NV SoS 🚀

thetinman

thetinman 7分前

You can't dispute any of the facts I've posted!
Typical. You get emotional the moment PTOP facts come up. Have you tried crying harder about my posts?

Btw — please SHOW me where I'm wrong about the lack of social media engagement and the stock price. I could post a picture of

Homebrew

Homebrew 8分前

QSEP's "rinse-repeat" PR dept's getting desperate. Their recycled, stale nonsense isn't working. This insider enrichment scheme isn't fooling anyone.

dexprs

OT: my first Monarch butterfly raised from an egg on his new native food was born and took flight, yesterday, the first in over a year since I changed from tropical milkweed to native. The native has a much lower odds of causing OE spores and a crippling disease to butterflies.

Aquahoya

Aquahoya 9分前

$FITY Something is coming down the pike. Decent volume today. Possible biotech merger if the new CEO plans to merge his company that has $10,000,000 undiluted funds.

$FITY had the cash to eat 600+ million shares at some price and cancel them before it hitting the market.

fink

Let the broke County DA subpoena I-hub for my info. I’ll be happy to take some heat off cohen. Make it about me. I’m cool with that. I still got your money.
She can’t afford to create a case against Cohen let alone a few mean tweets. But maybe she will get a few clicks for her algo.

12yearplan

12yearplan 9分前

ALM 17.79 pm
ALM 12% day. $17.07.

Investor082

Investor082 10分前

Exactly. The data is not convincing to say the least. Therefore, the best case scenario is restricted label and no reimbursement support for a couple of years.

It wouldn’t be surprising if the stock gets slammed on the news given how long this has taken and the history of NWBO in ter

NeWBrO

NeWBrO 11分前

Wow ! Unusual spread appearing in the pre-market OTC quote …
NWBO REAL-TIME LEVEL 2 QUOTE 6:44a on 6/12/26
0.0001 / 2,000.00 (10000 x 1)

bwmg

https://www.otcmarkets.com/stock/BWMG/news/Brownies-Marine-Group-and-Mountains-to-Seas-to-Showcase-Awake-Electric-Surfboards-at-Atlanta-Foil-Fest?id=524719

Green Leaf Smoker

Green Leaf Smoker 14分前

No magic kiss gonna wake up this POS PLAY MJNA as it's been declared dead for quite some time

Well I'll be damned MJNA goes down! Here's the BEAR link to POS MJNA ....Enough Said
https://investorshub.advfn.com/stock-market/USOTC/medical-marijuana-id-MJNA/trades#google_vig

t1215s

t1215s 14分前

Changnoi
Next comes the D. 4’s🤭😏😂
https://youtu.be/_zOjRlVpAOQ

Heck I would do the same with the freebies 🤭😏

GLTA-Ts🍻😎🇺🇸

Rattlershehe

Rattlershehe 14分前

As of March, there were approximately 154 million shares, as of today a little over 221 million so that’s about 70 million shares in three months. They need 42 million to close the deal. Doesn’t have to all be cash it can be shares however they need shareholder approval to give them those shares als

tryn2

Hey flip, I saw it on the MHRA website with my own eyes, but can't seem to find the screenshot that I took of it...

FanOfspringsteen

FanOfspringsteen 16分前

My3sons... Perhaps it's better for the price to rise steadily over several days; this allows for periods of consolidation and makes the increase more robust. This almost reassures me about its strength. This could very well be a groundswell that is taking shape.

Lime Time

Lime Time 17分前

This is a Hawkins company.

lol some are so jealous that we find these early before the run. Made huge money off Hawkins' tickers this year.

thetinman

thetinman 17分前

It's pathetic with all the news releases that stock has done nothing but drop to the lowest levels ever. 🙄

It's also pathetic the lack of information in the above mentioned press releases for a public company. 🙄

How many times over the years have you pos

just Scottie

just Scottie 18分前

Same! The whole private equity business man thesis really got me good.

imanjen13

imanjen13 19分前

Hopefully Elite will make an announcement to clarify the settlement of the patent dispute involving Oxy. The key here may be that Elite's Oxy patent # 217939 has ADT properties that make it safer and more desirable for patients.
The agreement also follows the old Shakesperean adage that the

Monksdream

Monksdream 19分前

DSY, there it goes

hnbadger1

hnbadger1 20分前

From Chat gpgt- Based on the information available so far, yes, blarcamesine is still slated to be part of the European ACCESS-AD program, despite the leadership changes at Anavex. The ACCESS-AD consortium selected blarcamesine as one of the therapies to be evaluated in its five-year European Commis

hnbadger1

hnbadger1 20分前

From Chat gpgt- Based on the information available so far, yes, blarcamesine is still slated to be part of the European ACCESS-AD program, despite the leadership changes at Anavex. The ACCESS-AD consortium selected blarcamesine as one of the therapies to be evaluated in its five-year European Commis

Specificity (PK)

iNAV Xtrackers II Target...

Invesco Municipal Opport...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。